drugset / Trial / NCT07573163

Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion

NCT07573163

Phase 2 Not yet recruiting 34 enrolled Alaa Sada
RandomizedParallel-groupOpen-labelTreatment

Summary

Mild Autonomous Cortisol Secretion (MACS) is a condition in which an adrenal gland produces excess cortisol and is associated with high blood pressure, diabetes, and weight gain. Surgical removal of the adrenal gland (adrenalectomy) is standard treatment, but some patients continue to have metabolic health problems after surgery. This randomized study will evaluate whether treatment with tirzepatide after adrenalectomy improves metabolic outcomes in patients with MACS compared with adrenalectomy alone.

Timeline

Start
2026-07
Primary completion
2028-07-31
Completion
2028-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tirzepatide Peptide 15 mg